2017 Press Releases


Keyword Search
2017 | 2016 | 2015 | 2014
DateTitle 
04/19/17Tocagen Announces Closing of Initial Public Offering and Exercise of the Underwriters' Option
SAN DIEGO, April 19, 2017 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced the closing of its initial public offering of common stock, including the underwriters' exercise of their option to purchase an additional 1,275,000 shares at the public offering price of $10.00 per share. The underwriters' option brought the total number of shares of common stock sold by Tocagen to 9,775,000 shares and increased the amount of gross proc... 
Printer Friendly Version
04/13/17Tocagen Announces Pricing of Initial Public Offering
SAN DIEGO, April 13, 2017 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced the pricing of its initial public offering of 8,500,000 shares of common stock at a public offering price of $10.00 per share. The shares are expected to begin trading on the NASDAQ Global Select Market on April 13, 2017 under the ticker symbol "TOCA." In addition, Tocagen has granted the underwriters a 30-day option to purchase up to an additional 1,275... 
Printer Friendly Version
03/16/17Tocagen to Present Anti-Tumor Immune Response Data at 2017 Keystone Symposia
SAN DIEGO – March 16, 2017 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced preclinical and clinical data will be presented at the 2017 Keystone Symposia on Molecular and Cellular Biology: Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology (C7), to be held March 19-23 in Whistler, British Columbia.Details of the poster presentation are as follows:Title: Preclinical and Clinical Data Support Anti-tumor Cellular Immune Response Elicit... 
Printer Friendly Version
03/07/17Tocagen Appoints Mark Foletta as Executive Vice President and Chief Financial Officer
SAN DIEGO – March 7, 2017 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced the appointment of Mark Foletta as executive vice president and chief financial officer, succeeding Tom Darcy, a company co-founder who is retiring. Mr. Darcy will continue to serve on the company's board of directors."Mark is a proven leader with deep experience building successful biopharmaceutical companies," said Marty Duvall, Tocagen's chief executive officer. "With the recent ... 
Printer Friendly Version
02/23/17Tocagen Achieves Key Development Milestone for Lead Product: Phase 2 Randomized Trial in Patients with Recurrent Brain Cancer Fully Enrolled Top-Line Results Anticipated 1H 2018
SAN DIEGO – Feb. 23, 2017 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced it has completed patient enrollment in the Phase 2 portion of Toca 5, a randomized, international Phase 2/3 clinical trial of Toca 511 & Toca FC, for the treatment of patients with recurrent brain cancer.Toca 5 is designed to serve as a potential registrational trial, and top-line results from the Phase 2 portion are anticipated in the first half of 2018. In the trial, patients with... 
Printer Friendly Version
02/23/17Tocagen Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Toca 511 & Toca FC in Recurrent High Grade Glioma
Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced the U.S. Food and Drug Administration (FDA) has granted Toca 511 & Toca FC Breakthrough Therapy Designation for the treatment of patients with recurrent high grade glioma (HGG). Toca 511 & Toca FC is currently under evaluation in an international, randomized Phase 2/3 clinical trial, which is designed to serve as a potential registrational study. The trial involves patients with first or second recurrence... 
Printer Friendly Version
01/17/17Tocagen to Present at Phacilitate Cell & Gene Therapy World 2017
SAN DIEGO – Jan. 17, 2017 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced Douglas J. Jolly, Ph.D., executive vice president, research and pharmaceutical development at Tocagen, will present at Phacilitate Cell & Gene Therapy World 2017, to be held Jan. 17-20 in Miami.Details of the podium presentation are as follows:Dr. Jolly's podium presentation will focus on gene therapy manufacturing and will be delivered on Wednesday, Jan. 18, 1:05-1:25 p.m. ET.About... 
Printer Friendly Version
01/13/17Tocagen Expands Toca 5, Phase 2/3 Clinical Trial for Recurrent Brain Cancer, to South Korea
SAN DIEGO – Jan. 13, 2017 — Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced its randomized, controlled Phase 2/3 clinical trial, called Toca 5, is now enrolling patients in South Korea. The trial is ongoing in the United States, Canada and Israel. The study compares a cancer-selective virus, Toca 511 (vocimagene amiretrorepvec), in combination with Toca FC (extended-release 5-fluorocytosine), to standard of care in patients with first or second recurre... 
Printer Friendly Version